Exelixis Gains 6.7% Post Q4 Earnings: Is This the Right Time to Buy?

Published on 18 Feb 2025 on Zacks · via Yahoo Finance

EXEL stock gains on the back of encouraging performance of its lead drug Cabometyx and impressive...

Read the rest of the article

Start tracking your investments with Statfolio

We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this...

Insider Monkey · via Yahoo Finance 23 Feb 2025

On Friday, Exelixis, Inc. (NASDAQ:EXEL) authorized repurchasing up to an additional $500 million ...

Benzinga · via Yahoo Finance 21 Feb 2025

Exelixis director Freire Maria C sells $1.54 million in stock

Investing.com 20 Feb 2025

In a recent transaction, Sue Gail Eckhardt, a director at Exelixis, Inc. (NASDAQ:EXEL), sold a to...

Investing.com 20 Feb 2025

In a recent filing with the Securities and Exchange Commission, Exelixis, Inc. (NASDAQ:EXEL)...

Investing.com 20 Feb 2025

EXEL stock gains on the back of encouraging performance of its lead drug Cabometyx and impressive...

Zacks · via Yahoo Finance 18 Feb 2025

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with t...

Zacks · via Yahoo Finance 14 Feb 2025

Exelixis, Inc. (NASDAQ:EXEL), a biotechnology company specializing in the development and...

Investing.com 15 Jan 2025

Estimates for 2024 loss per share have narrowed to 96 cents from $1.29 in the past 90 days....

Zacks · via Yahoo Finance 15 Jan 2025

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with t...

Zacks · via Yahoo Finance 13 Jan 2025